Nurix Therapeutics

(NASDAQ) NRIX

Current Price$16.28

Market Cap$1.65B

Since IPO (2020)-16%

5 Year-37%

1 Year+57%

1 Month-0%

Nurix Therapeutics Financials at a Glance

Market Cap

$1.65B

Revenue (TTM)

$71.78M

Net Income (TTM)

$295.28M

EPS (TTM)

$-3.16

P/E Ratio

-5.05

Dividend

$0.00

Beta (Volatility)

1.56 (High)

Dividend

$0.00

Beta (Volatility)

1.56 (High)

Price

$16.28

Volume

18,421

Open

$15.94

Price

$16.28

Volume

18,421

Open

$15.94

Previous Close

$15.96

Daily Range

$15.79 - $16.32

52-Week Range

$8.20 - $22.50

Dividend

$0.00

Beta (Volatility)

1.56 (High)

Price

$16.28

Volume

18,421

Open

$15.94

Previous Close

$15.96

Daily Range

$15.79 - $16.32

52-Week Range

$8.20 - $22.50

NRIX News

A Nurix Therapeutics (NRIX) Insider Sold 5,394 Shares for $90,000

Cory RenauerMay 6, 2026

Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million

Jonathan PoncianoFeb 22, 2026

Why Nurix Therapeutics Stock Soared More Than 21% Wednesday

James HalleyOct 27, 2021

NRIX: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Nurix Therapeutics

Industry

Biotechnology

Sector

Health Care

Employees

317

CEO

Arthur T. Sands, MD, PhD

Website

www.nurixtx.com

Headquarters

San Francisco, CA 94158, US

NRIX Financials

Key Financial Metrics (TTM)

Gross Margin

-1%

Operating Margin

-4%

Net Income Margin

-4%

Return on Equity

-61%

Return on Capital

-58%

Return on Assets

-46%

Earnings Yield

-19.80%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.65B

Shares Outstanding

103.41M

Volume

18.42K

Avg. Volume

1.07M

Financials (TTM)

Gross Profit

$65.12M

Operating Income

$285.67M

EBITDA

$244.84M

Operating Cash Flow

$249.47M

Capital Expenditure

$14.00M

Free Cash Flow

$263.47M

Cash & ST Invst.

$592.94M

Total Debt

$55.73M

Nurix Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$6.25M

-66.1%

Gross Profit

$77.89M

-52.1%

Gross Margin

-12.46%

N/A

Market Cap

$1.65B

N/A

Market Cap/Employee

$5.77M

N/A

Employees

286

N/A

Net Income

$87.17M

-54.7%

EBITDA

$92.50M

-52.8%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Net Cash

$482.08M

-7.8%

Accounts Receivable

$2.40M

N/A

Inventory

$0.00

N/A

Long Term Debt

$55.45M

+177.5%

Short Term Debt

$3.20M

-51.8%

Return on Assets

-46.42%

N/A

Return on Invested Capital

-57.97%

N/A

Free Cash Flow

$72.96M

-13.0%

Operating Cash Flow

$71.91M

-17.7%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

URGNUroGen Pharma Ltd.

URGNUroGen Pharma Ltd.$29.97+0.57%

FTREFortrea Holdings Inc.

FTREFortrea Holdings Inc.$14.27-2.33%

KODKodiak Sciences Inc.

KODKodiak Sciences Inc.$39.48-0.03%

EYPTEyePoint Pharmaceuticals, Inc.

EYPTEyePoint Pharmaceuticals, Inc.$13.53-0.70%

SEPNSepterna, Inc.

SEPNSepterna, Inc.$24.67-0.68%

PHATPhathom Pharmaceuticals, Inc.

PHATPhathom Pharmaceuticals, Inc.$12.57+0.36%

XNCRXencor, Inc.

XNCRXencor, Inc.$12.31-1.05%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$17.11+0.07%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$77.18+0.03%

BABAAlibaba Group

BABAAlibaba Group$145.81+0.08%

FFord Motor Company

FFord Motor Company$13.60+0.13%

NVDANvidia

NVDANvidia$227.19+0.03%

EOSEEos Energy Enterprises

EOSEEos Energy Enterprises$8.57+0.06%

NOKNokia

NOKNokia$14.45+0.10%

Questions About NRIX

What is the current price of Nurix Therapeutics?

Nurix Therapeutics is trading at $16.28 per share.

What is the 52-week range for Nurix Therapeutics?

Over the past 52 weeks, Nurix Therapeutics has traded between $8.20 and $22.50.

How much debt does Nurix Therapeutics have?

As of the most recent reporting period, Nurix Therapeutics reported total debt of $58.66M.

How much cash does Nurix Therapeutics have on hand?

Nurix Therapeutics reported $71.19M in cash and cash equivalents in its most recent financial results.

What is Nurix Therapeutics’s dividend yield?

Nurix Therapeutics does not currently have a dividend yield.

Nurix Therapeutics

Nurix Therapeutics Financials at a Glance

NRIX News

A Nurix Therapeutics (NRIX) Insider Sold 5,394 Shares for $90,000

Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million

Why Nurix Therapeutics Stock Soared More Than 21% Wednesday

NRIX: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Nurix Therapeutics

NRIX Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Nurix Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About NRIX

What is the current price of Nurix Therapeutics?

What is the 52-week range for Nurix Therapeutics?

How much debt does Nurix Therapeutics have?

How much cash does Nurix Therapeutics have on hand?

What is Nurix Therapeutics’s dividend yield?

Premium Investing Services